Do leukotriene receptor antagonists have a place in pharmacotherapy of allergic rhinitis?

Annals of Allergy, Asthma and Immunology

Volumn 90, Issue 5, 2003, Pages 466-468

  Nathan, Robert A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Asthma and Allergy PC and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIALLERGIC AGENT; FLUTICASONE; LORATADINE; QUINOLINE DERIVATIVE;

ALLERGIC RHINITIS; DRUG EFFICACY; EDITORIAL; MEDICAL RESEARCH; NOSE CONGESTION; PRIORITY JOURNAL; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HAY FEVER; HUMAN; INTRANASAL DRUG ADMINISTRATION; NOTE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ACETATES; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; HUMANS; LEUKOTRIENE ANTAGONISTS; LORATADINE; QUINOLINES; RANDOMIZED CONTROLLED TRIALS; RHINITIS, ALLERGIC, SEASONAL;

EID: 0038206456     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61837-6     Document Type: Editorial

References (25)

1. Ratner PH, Howland WC III, Arastu R, Philpot EE, Klein KC, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol. 2003;90:536-542.
2. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl):S147-S334.
3. Dykewiez MS, Fineman S. Executive summary of Joint Task Force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998;81:463-468.
4. Llanes SJ, Sur S, Grant JA, Alam R. Comparison of the effects of fluticasone and montelukast on early- and late-phase nasal allergic reactions. J Allergy Clin Immunol. 2001;107:S312.
5. Pullerits T, Praks L, Skoogh BE, Ani R, Lotvall J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med. 1999;159:1814-1818.
6. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109:949-955.
7. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy. 2001;31:61-68.
8. Wilson AM, Sims EJ, Orr LC, Coutie WJ, White PS, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2001;87:344-349.
9. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88:592-600.
10. Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020-1028.
11. 4-receptor antagonist, ICI 204, 219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 1995;151:1734-1739.
12. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105:917-922.
13. Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease." Ann Allergy Asthma Immunol. 2000;84:176-187.
14. Christodoulopoulos P, Cameron L, Durham S, Hamid Q. Molecular pathology of allergic disease. II: Upper airway disease. J Allergy Clin Immunol. 2000;105:211-223.
15. Druce HM, Kaliner MA. Allergic rhinitis. J Am Med Assoc. 1988;259:260-263.
16. Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy. 1996;26:868-879.
17. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol. 2003;90:182-191.
18. International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. Allergy 1994;49(Suppl):1-34.
19. Simons FE, Simons KJ. Optimum pharmacological management of chronic rhinitis. Drugs. 1989;38:313-331.
20. Meltzer EO. Nasal cytological changes following pharmacological intervention. Allergy. 1995;50(Suppl):15-20.
21. Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA, Van Natta M, Kesavan J, et al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol. 2002;109:794-799.
22. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy. 2001;31:616-624.
23. 1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998;317: 1624-1629.
24. Stempel DA, Thomas M. Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus non-sedating antihistamines. Am J Manag Care. 1998;4:89-96.
25. Maynard ML, Ernst ME. Leukotriene receptor antagonists in the treatment of allergic rhinitis. Ann Pharmacother. 2001;35:1274-1277.